

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10598416
Filing Date		2006-08-29
First Named Inventor		Stefan WILLMANN et al
Art Unit		
Examiner Name		
Attorney Docket Number		100717-691 KGB

U.S.PATENTS							<input type="button" value="Remove"/>
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS							<input type="button" value="Remove"/>
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button

FOREIGN PATENT DOCUMENTS								<input type="button" value="Remove"/>
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
/R.N./	1	101 60 270	DE		2003-06-26	BAYER AG		<input type="checkbox"/>
/R.N./	2	103 45 836	DE		2005-04-21	BAYER TECHNOLOGY SERVICES		<input type="checkbox"/>
/R.N./	3	103 45 837	DE		2005-04-21	BAYER TECHNOLOGY SERVICES		<input type="checkbox"/>

Receipt date: 02/23/2007

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10598416	10598416 - GAU: 1631
Filing Date	2006-08-29	
First Named Inventor	Stefan WILLMANN et al	
Art Unit		
Examiner Name		
Attorney Docket Number	100717-691 KGB	

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
/R.N./	1	Product Information - "Diprifusor™- Target Controlled Infusion (TCI) in anaesthetic practice"; AstraZeneca Anaesthesia, New Edition (1999), Alderley House, Alderley Park, UK	<input checked="" type="checkbox"/>
/R.N./	2	WILLMANN, Stefan et al; "PK-Sim®, a physiologically based pharmacokinetic 'whole-body' model"; Biosilico Vol. 1, No 4, (September 2003) pages 121-124, Elsevier Science Ltd.	<input checked="" type="checkbox"/>
/R.N./	3	PRICE, Paul S.; "Modeling interindividual variation in physiological factors used in PBPK models of humans"; Critical Reviews in Toxicology, 33(5); pages 469-503 (2003) Taylor and Francis, Inc.	<input checked="" type="checkbox"/>
/R.N./	4	OHNISHI, A.; "A review of clinical use of theophylline in acute asthma: factors influencing kinetic disposition and drug interactions"; Methods Find Exp. Clin Pharmacol 22(4); pages 253-258, (2000) Prous Science	<input checked="" type="checkbox"/>
/R.N./	5	MITENKO, Paul A, et al; "Pharmacokinetics of intravenous theophylline"; Clinical Pharmacology Therapeutics; 14, (1973) pages 509-513, Montreal, Quebec, Canada	<input checked="" type="checkbox"/>
/R.N./	6	JAMESON, John P., et al; "Theophylline Pharmacokinetics in black Zimbabwean males"; Therapeutic Drug Monitoring, 12, pages 54-58 (1990) Raven Press, Ltd. New York	<input checked="" type="checkbox"/>
/R.N./	7	GAL, Peter et al; "Theophylline disposition in obesity"; Clin. Pharmacol. Ther (April 1978), Vol. 23, No. 4; The C.V. Mosby Co., pages 438-444	<input checked="" type="checkbox"/>
/R.N./	8	JACKSON, S.H.D.; et al; "The relationship between theophylline clearance and age in adult life"; Eur. J. Clin Pharmacol, Springer-Verlag (1989) 36: pages 29-34	<input checked="" type="checkbox"/>
/R.N./	9	Kato et al. KATA, Z. et al; "Developmental changes of unbound theophylline"; Department of Pediatrics, Gifu University School of Medicine, 40 Tsukasa, Gifu 500 Japan	<input checked="" type="checkbox"/>

Receipt date: 02/23/2007

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10598416	10598416 - GAU: 1631
Filing Date	2006-08-29	
First Named Inventor	Stefan WILLMANN et al	
Art Unit		
Examiner Name		
Attorney Docket Number	100717-691 KGB	

/R.N./	10	VALENTI, S.; "Bioavailability and pharmacokinetics of a new controlled-release theophylline preparation in the form of capsules containing Pellets"; Respiration 52; (1987) pages 195-200	<input checked="" type="checkbox"/>
/R.N./	11	MULLER et al; "Theophylline kinetics in peripheral tissues in vivo in humans"; Naunyn-Schmiedeberg's Arch Pharmaol (1995) 352: pages 438-441	<input checked="" type="checkbox"/>
/R.N./	12	MEYER, Marvin c.; "Bioequivalence of immediate-release theophylline capsules"; Biopharmaceutics & Drug Disposition (1999) 20; pages 417-419	<input checked="" type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Russell Negin/	Date Considered	07/30/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.